Advanced search
Publication Cover
Cancer Biology & Therapy Volume 11, 2011 - Issue 6
Submit an article Journal homepage
472
Views
16
CrossRef citations to date
0
Altmetric
Clinical Study

Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker

Rajan Dewar Harvard Medical School and Beth Israel Deaconess Medical Center, Boston MA, USACorrespondence[email protected]
,
Sing-Tsung Chen Clarient Diagnostics Inc., Aliso Viejo, CA, USA
,
Heather Yeckes-Rodin Hematology-Oncology Associates, Stuart, FL, USA
,
Kenneth Miller Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA
&
Roya Khosravi-Far Harvard Medical School and Beth Israel Deaconess Medical Center; 5Biological and Biomedical Sciences (BBS) Program at Harvard Medical School, Boston MA, USACorrespondence[email protected]
Pages 552-558 | Received 29 Nov 2010, Accepted 29 Dec 2010, Published online: 15 Mar 2011

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Bruce Bostrom. (2016) Bortezomib for the treatment of acute lymphoblastic leukemia. Expert Opinion on Orphan Drugs 4:7, pages 775-780.
Read now
Junmei Zhao, Chao Wang, Yongping Song, Yuzhang Liu & Baijun Fang. (2015) Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy. International Journal of General Medicine 8, pages 211-214.
Read now
Françoise Huguet. (2015) Dasatinib for acute lymphoblastic leukemia. Expert Opinion on Orphan Drugs 3:11, pages 1339-1356.
Read now

Articles from other publishers (13)

Alba Orea-Soufi, Jihye Paik, José Bragança, Timothy A. Donlon, Bradley J. Willcox & Wolfgang Link. (2022) FOXO transcription factors as therapeutic targets in human diseases. Trends in Pharmacological Sciences 43:12, pages 1070-1084.
Crossref
Saskia Maletzke, Azam Salimi, Margherita Vieri, Kema Marlen Schroeder, Mirle Schemionek, Behzad Kharabi Masouleh, Tim H. Brümmendorf, Steffen Koschmieder & Iris Appelmann. (2022) Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia. PLOS ONE 17:10, pages e0268352.
Crossref
Chun-fung Sin & Pui-hei Marcus Man. (2021) The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia. Frontiers in Oncology 11.
Crossref
Xu Yang, Xuedong Wu, Na Fang, Xiaoping Liu, Xiaodan Liu, Lihua Yang, Ke Huang, Ailing Luo, Mansi Cai, Fan Wu, Hua Jiang & Ling Xu. (2019) FOXO3 gene polymorphisms influence the risk of acute lymphoblastic leukemia in Chinese children . Journal of Cellular Biochemistry 121:2, pages 2019-2026.
Crossref
Malihe Mirzaie, Mahboobeh Nasiri, Mehran Karimi, Majid Yavarian & Arghavan Kavosi. (2021) FoxO3a Gene Down-regulation in Pathogenesis of Pediatric Acute Lymphoblastic Leukemia. Indian Journal of Medical and Paediatric Oncology 40:03, pages 381-385.
Crossref
Boaz Nachmias, Adir Shaulov, Moshe E. Gatt, Michael Shapira & Alexander Gural. (2018) A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Acta Haematologica 140:4, pages 209-214.
Crossref
Francesca ConsolaroSadaf Ghaem-MaghamiRoberta BortolozziStefania ZonaMattaka KhongkowGiuseppe BassoGiampietro ViolaEric W.-F. Lam. (2015) FOXO3a and Posttranslational Modifications Mediate Glucocorticoid Sensitivity in B-ALL. Molecular Cancer Research 13:12, pages 1578-1590.
Crossref
Jessika Bertacchini, Neda Ketabchi, Laura Mediani, Silvano Capitani, Sandra Marmiroli & Najmaldin Saki. (2015) Inhibition of Ras-mediated signaling pathways in CML stem cells. Cellular Oncology 38:6, pages 407-418.
Crossref
HONG ZHU. (2014) Targeting forkhead box transcription factors FOXM1 and FOXO in leukemia (Review). Oncology Reports 32:4, pages 1327-1334.
Crossref
L J Crawford, E T Chan, M Aujay, T L Holyoake, J V Melo, H G Jorgensen, S Suresh, B Walker & A E Irvine. (2014) Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models. Oncogenesis 3:3, pages e90-e90.
Crossref
Octavian Bucur, Andreea Lucia Stancu, Ioana Goganau, Stefana Maria Petrescu, Bodvael Pennarun, Thierry Bertomeu, Rajan Dewar & Roya Khosravi-Far. (2013) Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells. PLoS ONE 8:10, pages e77390.
Crossref
Xiao-Li Du & Qi Chen. (2013) Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment. Acta Haematologica 129:4, pages 207-214.
Crossref
P.F. Seke Etet, L. Vecchio & A.H. Nwabo Kamdje. (2012) Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: Key role of stromal microenvironment. Cellular Signalling 24:9, pages 1883-1888.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.